CJC-1295 once-daily normalizes growth in GHRH knockout mice
Background
Isolated growth hormone deficiency is treatable with GHRH analogs in the majority of affected children, yet the extremely short half-life of native GHRH severely restricts therapeutic utility. Even twice-daily injections of conventional GHRH analogs have been shown to be insufficient to normalize growth in the GHRH knockout (GHRHKO) mouse model, which lacks endogenous GHRH signaling entirely. CJC-1295 is a synthetic long-acting GHRH analog engineered to covalently and selectively bind endogenous albumin after injection, dramatically extending circulating half-life and duration of action. This albumin-binding strategy makes once-daily or less-frequent dosing biologically plausible, a critical practical advantage over native GHRH. The GHRHKO mouse therefore provides a stringent benchmark for evaluating whether extended-release GHRH analogs can fully rescue the GH-deficient growth phenotype.
Study Design
Three groups of 1-week-old GHRHKO mice were treated for 5 weeks with 2 µg CJC-1295 administered subcutaneously at intervals of 24 h, 48 h, or 72 h. Placebo-treated GHRHKO mice and heterozygous GHRHKO control mice served as comparators. Primary endpoints included body weight, body length, femur and tibia length, relative lean mass, and subcutaneous fat mass. Pituitary somatotroph proliferation was assessed by measuring total pituitary RNA, GH mRNA via qPCR, and somatotroph cell number by immunohistochemistry.
Results
Animals receiving CJC-1295 every 24 h achieved fully normal body weight and body length, matching heterozygous controls. Mice dosed every 48 h and every 72 h showed partial improvements in body weight and length relative to placebo GHRHKO animals, but neither group reached full growth normalization. Femur and tibia lengths remained within normal range in the 24 h and 48 h treatment groups. Relative lean mass and subcutaneous fat mass were normal across all three treated groups, suggesting body composition benefits persisted even with less frequent dosing. CJC-1295 also drove increases in total pituitary RNA and GH mRNA, consistent with somatotroph cell proliferation.
Once-daily 2 µg CJC-1295 was the only dosing interval to fully normalize both body weight and body length in
GHRHKOmice, with immunohistochemistry confirming somatotroph expansion as a cellular correlate of this response.
Key Findings
- Once-daily 2 µg CJC-1295 fully normalized body weight and body length in GHRHKO mice
- Every-48 h and every-72 h dosing produced only partial growth normalization
- Femur and tibia lengths remained normal at 24 h and 48 h dosing intervals
- Relative lean mass and subcutaneous fat mass were normal in all three treated groups
- CJC-1295 increased total pituitary RNA and GH mRNA, confirmed by immunohistochemistry as somatotroph proliferation
Why It Matters
Dosing frequency is the decisive variable for CJC-1295 efficacy — every-24-hour administration is the threshold at which full growth rescue occurs in this model, while every-48-hour dosing yields only partial benefit despite the compound's extended half-life. For clinicians and protocol designers, this implies that the albumin-binding mechanism, though a major improvement over native GHRH, does not make dosing interval irrelevant. The finding of normalized body composition even at lower dosing frequencies is clinically relevant because it suggests fat and lean mass endpoints may have a lower pharmacological threshold than linear growth. From a translational standpoint, the demonstration that somatotroph cells proliferate in response to treatment raises important considerations for pediatric GH-deficiency protocols. Any stack combining CJC-1295 with IGF-1-axis agents should account for the pituitary-level changes documented here.
TitrateLab articles covering CJC-1295
Written by TitrateLab, separately from the study summarized above.
